Skip to main content
Milwaukee company to develop commercial version of cancer detection device

A commercial version of MarginScan, a device that detects cancerous cells using an impedance technology, will be developed by Milwaukee-based NovaScan for use in Mohs surgical treatment of skin cancer. The company, which will use the $2.5 million it recently raised in a $3.5 million financing round for product development, plans to initiate a pivotal trial next year and release the device in the US in 2019.

Full Story: